Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01482520

Enrollment

200

Registered

2011-11-30

Start date

2008-08-31

Completion date

2013-10-31

Last updated

2014-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma, Renal Cell Carcinoma

Brief summary

All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular targeted therapy will be candidates for the study. No additional treatment or intervention will be conducted except for blood sampling that will be limited to one time only. Blood samples (10 cc in volume) will be collected from all study participants once they provided written informed consent form. DNA will be extracted from peripheral blood samples using DNA isolation kit.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular targeted therapy will be candidates for the study

Design outcomes

Primary

Measure	Time frame	Description
Genotypes	36months	To define genotypes of HCC and RCC patients who will likely to response to molecular targeted therapy. To define genotypes associated with adverse events from molecular targeted. To identify genotypes which will predict survival or disease-free survival following molecular targeted therapy.

Countries

South Korea

Outcome results